Lyon, France – February 24, 2025 – Ventuno Biotech, a biotech company specializing in the development of innovative cancer immunotherapies, has officially been established. Co-founded by Jeremy Bastid, CEO and biotech entrepreneur, Nathalie Bonnefoy, Director of the IRCM Research Center in Montpellier, and the Octalfa company, Ventuno Biotech aims to achieve groundbreaking strides in the fight against cancer.
By leveraging cutting-edge research and technologies, Ventuno Biotech’s mission is to transform the treatment of certain cancers by developing novel therapeutic strategies to foster anticancer immunity.
Headquartered in Lyon, France, the company’s research laboratories are located at the prestigious Montpellier Cancer Research Institute IRCM in France. This strategic location offers Ventuno Biotech access to state-of-the-art facilities and the collaborative environment necessary for groundbreaking scientific discovery and innovations.
Jeremy Bastid, CEO of Ventuno Biotech, stated, “We are excited to announce the inception and launch of our new venture, Ventuno Biotech. Our team is committed to developing novel antibody therapies that have the potential to revolutionize cancer treatment. With the expertise of our founding members and the high-level scientific community around us, we are confident in our ability to make significant advancements in the field of cancer immunotherapy.”
Nathalie Bonnefoy, cofounder and Director of IRCM, added, “The creation of Ventuno Biotech is a natural extension of the collaborative research environment we have cultivated at IRCM. Together, we aim to accelerate the translation of our scientific discoveries in the field of cancer immunology and tumor microenvironment into novel potential therapeutic strategies against breakthrough cancer targets.”
Octalfa, a founding member and incubator of this project, brings its experience in company inception and management, further strengthening its position in the biotech ecosystem. Octalfa will serve as the President of the company and will also be the lead investor in the first funding round, which is expected to close before the summer.
Ventuno Biotech’s mission is to bridge the gap between cutting-edge academic research and potential breakthrough immunotherapies, delivering innovations that address the unmet needs of cancer patients. The research programs Ventuno Biotech have not been disclosed yet.
Download the press release (pdf).
For more information about Ventuno Biotech, please contact:
Jeremy BASTID
CEO
Jeremy.bastid@ventuno-biotech.com
Tel: +33 (0)4 37 49 87 20
About Ventuno Biotech
Ventuno Biotech is a biotechnology company focused on the development of innovative cancer immunotherapies. Based in Lyon, France, with research laboratories located at the IRCM (Montpellier Cancer Research Institute, France), Ventuno Biotech leverages cutting-edge scientific research and breakthrough technologies to develop novel immunotherapies that harness the body’s immune system to fight cancer. Founded by Jeremy Bastid, CEO, Nathalie Bonnefoy, Director of IRCM, and Octalfa, Ventuno Biotech aims to transform the landscape of cancer immunotherapy.
For more information, visit www.ventuno-biotech.com.
About Octalfa
Founded in 2007, Octalfa is a family-owned investment company active in three areas: minority shareholdings, business creation, and company acquisitions alongside management teams. To date, we have invested in 15 companies and co-founded two innovative life sciences ventures. Since 2009, in parallel, the Dominique and Tom Alberici – Octalfa Corporate Foundation has supported charitable projects providing direct benefits to individuals affected by cancer or living with disabilities. More than 210 initiatives have already been supported.
For more information, visit www.initiative-octalfa.eu